EG-R mRNA Delivery System
EG-R can be used for an mRNA delivery carrier.
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Brand name
- EG-R mRNA Delivery System
- Payment Terms
- Others
- Production method
- Available
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- lyophilization, mrna, liposome, delivery system
- Category
- Medicines , Other Pharmaceuticals , Pharmaceutical Intermediates
Product name | EG-R mRNA Delivery System | Certification | - |
---|---|---|---|
Category |
Medicines
Other Pharmaceuticals Pharmaceutical Intermediates |
Material | CATIONIC LIPOSOME |
Keyword | lyophilization , mrna , liposome , delivery system | Unit Size | - |
Brand name | EG-R mRNA Delivery System | Unit Weigh | - |
origin | South Korea | Stock | 1 |
Supply type | Available | HS code | - |
Product Information
A liposome is a spherical-shaped vesicle that is composed of phospholipid bilayers, which closely resembles the structure of cell membranes, and exhibited biocompatibility and biodegradability.
Liposomes have long been used as drug delivery or adjuvant for human vaccine. Here, we suggested novel cationic liposome-based mRNA delivery systems called EG-R. EG-R are composed of a cationic lipid, 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and helper lipid.
EG-R can be used for an mRNA delivery carrier. Complexes of Renilla luciferase mRNA and EG-R were intramuscularly injected into mice and observed that the expression of Renilla luciferase was successfully achieved.
Moreover, we prepared a lyophilized form of Renilla luciferase mRNA and EG-R complex and confirmed that the lyophilized form is likely deliver mRNA as efficient as liquid form. Taken together, we suggested the EG-R is efficient mRNA delivery system for various type of mRNA vaccines.
<EG-R can be prepared as a freeze-dried (lyophiliztion) form>
▶Freeze-dried ER-G overcomes many hurdles in vaccine equity through the use of a simple household refrigator (no expensive cryogenic system required)
▶ Conveniently transported, managed and administered with a long shelf life
▶ Relatively inexpensive to distribute to low-income countries
1. Delivery Efficiency
▶EG-R lipolex observed that the locally expression of Renilla luciferase was successfully achieved.
2. East to Applicate
▶ EG-R lipolex can be applicated infectious disease, Therapeutics for OA and Cancer Vaccines.
3. Biodistribution of EG-R system
▶EG-R lipoplex was observed localized expression pattern of biodistribution.
4. Safety Profile
▶Suspicions grow that nanoparticle(LNP) in some COVID-19 vaccine trigger rare allergic reactions due to PEG hypersensitivity.
▶No issue with Toxicology result.
5. Preclinical Efficacy Profile
▶EG-R demonstrated humoral immunity, CMI and Neutralization activity for SARS-COV-2 WT.
6. Stability at 4℃
▶Lyophilized EG-R lipoplexes at 4℃ for up to 8 weeks show no change in physical characteristics.
7. Long-Term Stabiligy of DP at 4℃
▶The mRNA vaccine complexed with EG-R, DP(EG-COVID) is proved to be very stable stored at 2-8℃ up to 6 months.
- Product Info Attached File
B2B Trade
Price (FOB) | Negotiable | transportation | Negotiation Other |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | Others | Shipping time | Negotiable |
- President
- Wonil Yoo
- Address
- b-910, 401 Yangcheon-ro, Gangseo-gu, Seoul, Korea
- Product Category
- Other Chemicals
- Year Established
- 2000
- No. of Total Employees
- 51-100
- Company introduction
-
Eyegene took its first step in the development of innovative biopharmaceutical drugs when it was first established in june 2020.
Since then, Eyegene has continued to research and develop innovative drugs to overcome the deterioration of the quality of life due to aging.
Eyegene has two core technologies. EGT022 os a molecule for the treatment of ischemic diseases based on proteomic research. It is being developed as a treatment for diabetic retinopathy, pressure ulcers, wound healing, and Myocardial ischemia/Reperfusion Injury. Various Premium Vaccines for adults are also being developed using Eyegene's proprietary Adjuvant, which has been established through continuous research in the field of immunology.
- Main Markets
-
Argentina
Brazil
India
Indonesia
Viet Nam
- Main Product
- Attached File
Related Products
2,3,4,4'-Tetrehydroxybenzophenone, CAS NO.: 31127-54-5
Eriocitrin
Botalinum Ampoule
Betamethasone 17-valerate
Water Soluble Chitosan